

MINI REVIEW

## Presynaptic autoreceptors in the third decade: focus on $\alpha_2$ -adrenoceptors

Klaus Starke

*Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Freiburg, Germany*

Presynaptic autoreceptors were discovered by six groups of researchers in 1971. The receptors of 1971 were autoreceptors regulating the release of noradrenaline, acetylcholine and GABA (Starke *et al.* 1989).

The first 10 years after 1971 yielded the basic evidence. Carlsson (1975) coined the term 'autoreceptors', receptors 'sensitive to the neuron's own transmitter substance'. It was recognized that neurons may also possess autoreceptors in their soma-dendritic region. The second 10 years brought important pharmacological consequences: just like presynaptic  $\alpha$ -autoreceptors had been the first  $\alpha_2$ -adrenoceptors (Langer 1974), presynaptic serotonin autoreceptors now became the prototypical 5-HT<sub>1</sub>-receptors, presynaptic histamine autoreceptors the prototypical H<sub>3</sub>-receptors (Starke *et al.* 1989), and presynaptic glutamate autoreceptors activated by L-2-amino-4-phosphonobutyrate (L-AP4) became the prototypical metabotropic glutamate receptors (Monaghan *et al.* 1989). The second 10 years also witnessed a spirited denial of the function, and even the existence, of autoreceptors (Kalsner 1982; Starke 1987; Kalsner and Westfall 1990), an assault that, I believe, miscarried because the observations spoke, and speak, for themselves.

The purpose of this article is to summarize events of the third decade of autoreceptor research, following our review of 1989 (Starke *et al.* 1989). Novel features comprised the further pharmacological classification of the autoreceptors, their molecular identification, their study by means of receptor-deficient animals and a detailed elucidation of their signal transduction. These research steps of the third decade were common to presynaptic autoreceptors. However, instead of giving a general survey here, which would have to remain superficial, I shall discuss one group of autoreceptors at some depth, the release-inhibiting  $\alpha_2$ -autoreceptors of noradrenergic neurones. They were the first in which an inhibitory effect of the transmitter itself was demonstrated (Starke 1972). They are among the best-studied, and their study is representative of the study of other presynaptic autoreceptors. However, attention should be drawn to the fact that presynaptic glutamate autoreceptors, with ionotropic and metabotropic and with inhibitory and facilitatory members, were a focal point of interest in the last 10 years (MacDermott *et al.* 1999).

### $\alpha_2$ -Autoreceptors: $\alpha_2$ -adrenoceptor subclassification


Presynaptic  $\alpha_2$ -autoreceptors were not only the prototype  $\alpha_2$ -adrenoceptors (see above). Their study also showed first that  $\alpha_2$ -adrenoceptors were not one single receptor type: they differed between rats and rabbits (Hieble *et al.* 1997). Radioligand binding experiments then indicated that there were four pharmacologically distinct  $\alpha_2$ -adrenoceptors,  $\alpha_{2A}$ ,  $\alpha_{2B}$ ,  $\alpha_{2C}$  and  $\alpha_{2D}$  (Bylund *et al.* 1994). On the basis of molecular genetic studies it is now generally accepted that many mammalian species including humans, rats, mice and guinea pigs possess three  $\alpha_2$ -adrenoceptor genes, of which one codes for the  $\alpha_{2A/D}$ -adrenoceptor, one for the  $\alpha_{2B}$ -adrenoceptor and one for the  $\alpha_{2C}$ -adrenoceptor. The designation  $\alpha_{2A/D}$  mirrors the fact that small differences in amino acid sequence lead to notable species differences in the pharmacological properties of this receptor, the receptor with  $\alpha_{2A}$  pharmacology (characterized for example by an antagonist affinity ratio phentolamine  $\ll$  yohimbine, rauwolscine) occurring in humans and rabbits and the orthologous receptor with  $\alpha_{2D}$  pharmacology (characterized, for example, by an antagonist affinity ratio phentolamine  $\geq$  yohimbine, rauwolscine) in rodents. Part of the pharmacological difference can be attributed to a point mutation in the fifth transmembrane domain of this receptor where cysteine in humans is replaced by serine in mice and rats (Link *et al.* 1992; Bylund *et al.* 1994; Hieble *et al.* 1997; Hein 2001).

### $\alpha_2$ -Autoreceptors: subtype determination

With the genetic trichotomy of  $\alpha_2$ -adrenoceptors established, the question arose to which subtype or subtypes the presynaptic  $\alpha_2$ -autoreceptors belonged. Comparison of antagonist potencies at the autoreceptors with their affinities for prototypical  $\alpha_{2A}$ ,  $\alpha_{2B}$ ,  $\alpha_{2C}$  and  $\alpha_{2D}$  binding sites indicated that presynaptic autoreceptors were at least predominantly  $\alpha_{2A}$  in humans and rabbits and  $\alpha_{2D}$  in rats and mice, i.e. belonged to the genetic  $\alpha_{2A/D}$  branch with its two orthologous varieties, or in other words: mammals seemed to express mainly the  $\alpha_{2A/D}$  gene in noradrenergic neurones to bring these neurones under  $\alpha_2$ -autoreceptor

Received November 30, 2000; accepted May 14, 2001.

Address and reprint requests to Dr Klaus Starke, Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Hermann-Herder-Strasse 5, D-79104 Freiburg i.Br., Germany.



**Fig. 1** Inhibition by the  $\alpha_2$ -adrenoceptor agonist UK-14304 of electrically evoked [ $^3$ H]noradrenaline release in atria from wild-type mice (WT) and mice in which either the  $\alpha_{2A/D}$ -adrenoceptor gene, the  $\alpha_{2B}$ -adrenoceptor gene, the  $\alpha_{2C}$ -adrenoceptor gene or both the  $\alpha_{2A/D}$ - and the  $\alpha_{2C}$ -adrenoceptor gene had been disrupted. From Hein *et al.* (1999).

control (Trendelenburg *et al.* 1993; Limberger *et al.* 1995; Guimarães *et al.* 1998; Feuerstein *et al.* 2000; Docherty 1998). The identification was unambiguous for cerebral noradrenergic neurones. It was less clear-cut for post-ganglionic sympathetic neurones. The autoreceptors of the sympathetic fibres of the human kidney and human atria, for example, were initially classified as  $\alpha_{2C}$  (Trendelenburg *et al.* 1994a; Rump *et al.* 1995; but also see Trendelenburg *et al.* 1997), and the autoreceptors of rat and mouse atria also did not show pure  $\alpha_{2D}$  characteristics (Limberger *et al.* 1992; Wahl *et al.* 1996).

The generation of mice with disruptions of the  $\alpha_{2A/D}$ ,  $\alpha_{2B}$  or  $\alpha_{2C}$  gene ( $\alpha_{2A/D}$  KO,  $\alpha_{2B}$  KO,  $\alpha_{2C}$  KO) offered a novel approach to the problem. These studies have confirmed the suggestion that the main mammalian presynaptic  $\alpha_2$ -autoreceptors are  $\alpha_{2A/D}$  (Altman *et al.* 1999; Hein *et al.* 1999; Trendelenburg *et al.* 1999, 2001a, 2001b). For example, the maximal inhibition of noradrenaline release produced by the selective  $\alpha_2$ -adrenoceptor agonist medetomidine in the hippocampus and occipito-parietal cortex was reduced from almost total in wild-type preparations to about 37% in  $\alpha_{2A/D}$  KO preparations, and in atria and the vas deferens it was reduced from almost total (wild-type) to about 77% ( $\alpha_{2A/D}$  KO; Trendelenburg *et al.* 1999). In contrast, the maximal inhibition of noradrenaline release produced by medetomidine was not changed in the hippocampus, the occipito-parietal cortex, atria and the vas deferens of  $\alpha_{2B}$  KO or  $\alpha_{2C}$  KO mice (Altman *et al.* 1999; Trendelenburg *et al.* 2001b). However, some inhibition by medetomidine remained in all  $\alpha_{2A/D}$  KO tissues. Interestingly, this remaining, non- $\alpha_{2A/D}$ -adrenoceptor-mediated inhibition was greater (~77% maximally) in atria and the vas deferens than in the hippocampus and the occipito-parietal cortex (~37% maximally), as mentioned, in accord with the notion from studies with series of antagonists that it was

in peripheral tissues that the pharmacology of the autoreceptors deviated from pure  $\alpha_{2A}$  or  $\alpha_{2D}$  characteristics. The nature of the non- $\alpha_{2A/D}$ -autoreceptor in mouse atria was clarified when Hein *et al.* (1999) generated mice that lacked both the  $\alpha_{2A/D}$ - and the  $\alpha_{2C}$ -adrenoceptor ( $\alpha_{2AC}$  KO). Figure 1 shows the effect of the  $\alpha_2$  agonist UK-14304 on the electrically evoked release of noradrenaline in atria taken from wild-type and the various KO mice. The maximal inhibition obtained in wild-type atria was near 100%, and this was not changed when the tissues lacked the  $\alpha_{2B}$ - or  $\alpha_{2C}$ -adrenoceptor. In atria lacking the  $\alpha_{2A/D}$ -adrenoceptor, the maximal inhibition was reduced to 70% (Fig. 1). When the  $\alpha_{2C}$ -adrenoceptor had been deleted in addition to the  $\alpha_{2A/D}$ -adrenoceptor to produce  $\alpha_{2AC}$  KO animals, however, this remaining inhibition was lost and UK-14304 failed to produce any effect (Fig. 1). The non- $\alpha_{2A/D}$ -autoreceptors in mouse atria hence were  $\alpha_{2C}$ . The same was true for the mouse brain cortex, except that here the non- $\alpha_{2A/D}$  component was smaller (Hein *et al.* 1999). So when one extrapolates beyond the species and tissues tested, mammals possess two presynaptic  $\alpha_2$ -autoreceptors,  $\alpha_{2A/D}$ -autoreceptors which predominate, and  $\alpha_{2C}$ -autoreceptors, which are more prominent in peripheral tissues than in the brain. The failure of deletion of the  $\alpha_{2C}$ -adrenoceptor alone to produce any change indicates that, as long as  $\alpha_{2A/D}$ -adrenoceptors are present they suffice for full autoreceptor function, at least as examined by means of an exogenous agonist (however, see section on physiological operation below).

The  $\alpha_2$ -autoreceptor subtype has also been examined in post-ganglionic sympathetic neurones from newborn mice kept in primary culture. As shown in Fig. 2(a), UK 14,304 greatly reduced the electrically evoked release of noradrenaline from wild-type cultures. Phentolamine was a more potent antagonist against UK 14,304 than rauwolscine, giving the typical  $\alpha_{2D}$  antagonist potency ratio phentolamine > rauwolscine. In accord with this diagnosis, no inhibition whatsoever remained when the  $\alpha_{2A/D}$  gene had been disrupted (Fig. 2b): the presynaptic autoreceptors were purely  $\alpha_{2A/D}$  (i.e. pharmacologically  $\alpha_{2D}$ ). No  $\alpha_{2C}$  admixture as in adult mouse sympathetically innervated tissues was found, perhaps because the expression of  $\alpha_{2C}$ -autoreceptors begins only a couple of days after birth (see section on development below).

The soma-dendritic  $\alpha_2$ -autoreceptors of noradrenergic neurones mediate an increase in potassium conductance, a decrease in calcium currents and therefore inhibition. Their subtype has been investigated both in the locus coeruleus and in sympathetic ganglion cells. Studies with antagonists showed that, in the intact rat locus coeruleus, the main soma-dendritic  $\alpha_2$ -autoreceptors mediating hyperpolarization and a decrease of firing were  $\alpha_{2A/D}$  (Nörenberg *et al.* 1997; Mateo and Meana 1999). However, an induction of inwardly rectifying potassium currents in acutely dissociated

rat locus coeruleus neurones was mediated by  $\alpha_{2B}$ - or  $\alpha_{2C}$ -adrenoceptors (Arima *et al.* 1998). In the cultured mouse sympathetic neurones mentioned above, the major part of the inhibition of calcium currents caused by UK 14,304 was mediated by  $\alpha_{2A/D}$ -adrenoceptors. However, some inhibition remained in neurones taken from  $\alpha_{2A/D}$ KO mice, indicating a component of  $\alpha_{2B}$ - or  $\alpha_{2C}$ -adrenoceptors (Trendelenburg *et al.* 2001a). So when one extrapolates again, in accord with presynaptic  $\alpha_2$ -autoreceptors mammals seem to possess two soma-dendritic  $\alpha_2$ -autoreceptors,  $\alpha_{2A/D}$ -adrenoceptors which predominate, and a minor population of either  $\alpha_{2B}$ - or  $\alpha_{2C}$ -adrenoceptors.


The question of differences between  $\alpha_2$ -autoreceptors and other  $\alpha_2$ -adrenoceptors has interested many researchers, inter alia because of possible therapeutic consequences. So-called  $\alpha_2$ -heteroreceptors occur on cerebral serotonergic terminal axons where they inhibit the release of serotonin. Studies with series of antagonists indicated that, in the brain of rats and rabbits, the presynaptic  $\alpha_2$ -autoreceptors and the heteroreceptors at the serotonergic axons were similar, both being mainly  $\alpha_{2A}$  in rabbits and  $\alpha_{2D}$  in rats (Trendelenburg *et al.* 1994b). This conclusion has now also been confirmed in genetically manipulated mice. Like the  $\alpha_2$ -autoreceptors, the heteroreceptors in the hippocampus were a mixture of predominant  $\alpha_{2A/D}$ - and minor  $\alpha_{2C}$ -adrenoceptors. The serotonin release-inhibiting effect of the agonist medetomidine was reduced in  $\alpha_{2A/D}$ KO and  $\alpha_{2C}$ KO tissues and disappeared completely when both receptors had been eliminated, i.e. in  $\alpha_{2AC}$ KO tissues (Scheibner *et al.* 2001a).

#### $\alpha_2$ -Autoreceptors: in search for the molecules

For many years researchers have tried to label  $\alpha_2$ -autoreceptors by radioligands, with limited success (Starke 1987; Starke *et al.* 1989). The cloning of the three  $\alpha_2$ -adrenoceptor genes opened up new possibilities.

One major result has been the demonstration that noradrenergic neurones express the  $\alpha_{2A/D}$ -adrenoceptor gene as studied by *in situ* hybridization of the mRNA. This has been shown both in noradrenergic brain nuclei, especially the locus coeruleus, of rats (Nicholas *et al.* 1993; Scheinin *et al.* 1994; Winzer-Serhan *et al.* 1997a) and mice (Wang *et al.* 1996) and in the rat superior cervical ganglion (Vidovic *et al.* 1994). In fact, 'the most intense hybridization signal in the entire rat brain was seen with the  $\alpha_{2A}$  probe

in the locus coeruleus', and the authors suggest that 'this receptor subtype functions as a presynaptic autoreceptor in the rat brain' (Scheinin *et al.* 1994).  $\alpha_{2B}$ - and  $\alpha_{2C}$ -adrenoceptor mRNA was not detected in noradrenergic



**Fig. 2** Inhibition by the  $\alpha_2$ -adrenoceptor agonist UK-14304 of electrically evoked release of [ $^3\text{H}$ ]noradrenaline in cultures of post-ganglionic sympathetic neurones taken from newborn wild-type or  $\alpha_{2A/D}$ -adrenoceptor-deficient mice. (a) Interaction of UK-14304 with antagonists in neurones from wild-type mice. (b) Comparison of neurones from wild-type and  $\alpha_{2A/D}$ KO mice. (c) Effect of pretreatment of wild-type cultures with pertussis toxin. From Trendelenburg *et al.* (2001a).

cells or was detected only in very small amounts (Vidovic *et al.* 1994; Winzer-Serhan *et al.* 1997b).

A second major result was the immunological demonstration of both the  $\alpha_{2AD}$ - and the  $\alpha_{2C}$ -adrenoceptor protein in cerebral noradrenergic nuclei, in particular the locus coeruleus (Rosin *et al.* 1993, 1996). The proteins were located at least partly in the membrane of the noradrenergic neurone dendrites (Lee *et al.* 1998a,b).

So both the mRNA and the protein studies agree well with the functional studies: the molecules functioning as  $\alpha_2$ -autoreceptors, i.e. mainly  $\alpha_{2AD}$ - and to a minor extent  $\alpha_{2C}$ -adrenoceptors, are in fact synthesized, and present, in noradrenergic neurones. However, some gaps in this correspondence of function and protein presence remain. Although cerebral soma-dendritic  $\alpha_2$ -autoreceptors have been demonstrated immunologically as proteins in the appropriate dendritic membranes, an analogous demonstration of an axon terminal, i.e. presynaptic,  $\alpha_2$ -autoreceptor protein in the brain has not yet been achieved. Moreover,  $\alpha_2$ -adrenoceptor proteins have not been demonstrated on peripheral post-ganglionic sympathetic neurones.

The latter gap may soon be filled. Olli-Lähdesmäki *et al.* (1999) transfected rat pheochromocytoma (PC12) cells, which have many similarities with post-ganglionic sympathetic neurones, with the human  $\alpha_{2AD}$ -,  $\alpha_{2B}$ - and  $\alpha_{2C}$ -adrenoceptor genes and then visualized the receptors with immunocytochemistry. When differentiation and axon growth were induced by nerve growth factor, the  $\alpha_{2B}$ -adrenoceptors were evenly distributed over the plasma membrane. The  $\alpha_{2C}$ -adrenoceptors were found mainly intracellularly. The  $\alpha_{2AD}$ -adrenoceptors, however, were targeted to the membrane of growth cones and later seen in the distal segments of the axons: the very places where they could inhibit neurotransmitter release.

#### **$\alpha_2$ -Autoreceptors: signal transduction**


Soon after the discovery of presynaptic  $\alpha_2$ -autoreceptors, the idea emerged that they modified calcium movements in noradrenergic terminal axons (Starke and Montel 1974; Göthert 1977; see Starke 1987; Starke *et al.* 1989). With the discovery that all  $\alpha_2$ -adrenoceptors couple to heterotrimeric G-proteins, the first signal transduction step was also identified. Much of the presynaptic  $\alpha_2$ -adrenergic inhibition is blocked by pertussis toxin (Fig. 2c), but some inhibition may also operate through pertussis toxin-insensitive G-proteins (Allgaier *et al.* 1985; Boehm *et al.* 1992; Hill *et al.* 1993; Koh and Hille 1997; Schwartz 1997). The  $\alpha_2$ -adrenergic inhibition of noradrenaline release from chick cultured sympathetic neurones operated only as long as release was due to calcium entry through N-type channels, suggesting that presynaptic N-type calcium channels were the only target of the  $\alpha_2$ -autoreceptor-G-protein signal transduction pathway (Boehm and Huck 1996).

The conclusions so far were drawn from noradrenaline release studies. More details have been suggested by studies on soma-dendritic  $\alpha_2$ -autoreceptors, most frequently in the rat superior cervical ganglion, because only the soma-dendritic receptor mechanisms are accessible to electrophysiological measurements. These studies have led to the following hypothesis. In rat superior cervical sympathetic ganglion cells, agonist activation of soma-dendritic  $\alpha_2$ -autoreceptors leads primarily to activation of  $G_o$  or  $G_i$ , i.e. dissociation of  $G_o$  into  $G_{o\alpha}$  and the corresponding  $\beta\gamma$ -complex and dissociation of  $G_i$  into  $G_{i\alpha}$  and the corresponding  $\beta\gamma$ -complex. The  $\beta\gamma$ -complexes then are more important than the  $G_{\alpha}$  subunits in continuing signal transduction. The  $\beta\gamma$ -complexes interact directly, without intercalation of a cytoplasmic second messenger, with the pore-forming  $\alpha_1$  subunits of N- and P/Q-type calcium channels, thus reducing the channels' open probability. The  $\alpha_2$ -adrenoceptor- $G_o$  pathway seems to predominate; it is pertussis toxin-sensitive, rapid and voltage-dependent: depolarization alleviates the block of the calcium channel. The  $\alpha_2$ -adrenoceptor- $G_i$  pathway is pertussis toxin-resistant, slow and voltage-insensitive (Delmas *et al.* 1999; Kaneko *et al.* 1999). The specific  $G_{o\alpha}$  proteins in rat superior cervical ganglion cells seem to be  $G_{o\alpha A}$  and  $G_{o\alpha B}$ , and the specific  $G_{i\alpha}$  protein seems to be  $G_{i\alpha 2}$  (Jeong and Ikeda 2000). Whether the same  $\alpha_2$ -adrenoceptor subtype couples to both  $G_o$  and  $G_i$ , or whether different subtypes couple to each G-protein selectively, is not known. In cultured mouse post-ganglionic sympathetic neurones, pertussis toxin blocked both the  $\alpha_{2AD}$ -adrenoceptor-mediated and the non- $\alpha_{2AD}$ -adrenoceptor mediated inhibition of calcium currents (Trendelenburg *et al.* 2001a).

However fascinating this elaborate hypothesis is, it should be remembered that it is based on observations on soma-dendritic receptors. If applicable to presynaptic autoreceptors, it might explain for example why the inhibition of noradrenaline release through  $\alpha_2$ -autoreceptors (as well as presynaptic heteroreceptors such as cannabinoid receptors) declines at high frequencies (Göbel *et al.* 2000): high frequency depolarization might remove the voltage-sensitive part of the  $\beta\gamma$  blockade of N-type calcium channels. However, some observations on presynaptic  $\alpha_2$ -adrenergic inhibition are hard to understand on the basis of any inhibition of calcium entry through voltage-sensitive channels. Other possible modes of inhibition such as direct interference with the exocytotic machinery should be kept in mind (Jackisch *et al.* 1992; Schwartz 1997; Smith and Cunnane 1998).

#### **$\alpha_2$ -Autoreceptors: physiological operation**

The question of the physiological operation of autoreceptors is whether, apart from being targets of exogenous agonists, the autoreceptors are also activated by previously released transmitters itself. The question was the core issue of the



**Fig. 3** Pulse number– $^3\text{H}$ noradrenaline release relationships in the brain cortex of wild-type mice and mice in which either the  $\alpha_{2A/D}$ -adrenoceptor gene, the  $\alpha_{2B}$ -adrenoceptor gene or the  $\alpha_{2C}$ -adrenoceptor gene had been disrupted. Frequency of stimulation was 1 Hz. Tissues were superfused either with rauwolscine-free


medium or with medium containing 1  $\mu\text{M}$  rauwolscine. Dotted lines in b to d represent wild-type release in the absence of rauwolscine (from a). Significant differences from wild-type, no rauwolscine: # $p < 0.05$ . Significant effects of rauwolscine: \* $p < 0.05$ . Modified from Trendelenburg *et al.* (2001b).

struggle, mentioned in the Introduction, that arose in the second decade of autoreceptor research. The most important observation to support an endogenous presynaptic  $\alpha_2$  autoinhibition is the uniform release-enhancing effect of  $\alpha_2$ -adrenoceptor antagonists (Starke *et al.* 1989). Again, mice in which  $\alpha_2$ -adrenoceptor genes are disrupted offer a new test.

In initial studies, deletion of the  $\alpha_{2A/D}$ -adrenoceptor increased the release of noradrenaline from mouse atria, vas deferens, occipito-parietal cortex and hippocampus (Hein *et al.* 1999; Trendelenburg *et al.* 1999). In atria, deletion of the  $\alpha_{2C}$ -adrenoceptor also increased the release of noradrenaline, and release was increased even more when both receptors were deleted to yield  $\alpha_{2AC}$ KO atria (Hein *et al.* 1999). These investigations confirmed the classical work with  $\alpha_2$ -adrenoceptor antagonists and showed that the autoreceptors indeed mediated a physiological negative feedback.

More recently, effects of both gene disruptions and the  $\alpha_2$  antagonist rauwolscine have been examined in several mouse tissues over a wide range of stimulation pulse numbers and stimulation frequencies (Scheibner *et al.* 2001b; Trendelenburg *et al.* 2001b). Figure 3 shows the pulse

number-noradrenaline release relationship in the brain cortex of wild-type,  $\alpha_{2A/D}$ KO,  $\alpha_{2B}$ KO and  $\alpha_{2C}$ KO mice, the frequency being constant (1 Hz). In wild-type brain cortex in the absence of rauwolscine, the pulse number-release curve was flat, release by  $p$  pulses being much lower than  $p$  times the release by a single pulse, and rauwolscine did not increase the release elicited by a single pulse but increased greatly the release elicited by 2 or more pulses, thus rendering the curve much steeper (Fig. 3a). In  $\alpha_{2B}$ KO and  $\alpha_{2C}$ KO brain cortex there was no change from wild-type (Figs 3c and d). Only deletion of the  $\alpha_{2A/D}$ -adrenoceptor changed the pattern; in the  $\alpha_{2A/D}$ KO brain cortex, the pulse number-release curve was steepened, release by  $p$  pulses being much closer to  $p$  times the release by a single pulse, and rauwolscine increased the release of noradrenaline but slightly (Fig. 3b). Essentially similar results were obtained in the hippocampus, in atria and in the vas deferens. So in all tissues,  $\alpha_2$ -autoinhibition greatly depressed (and its removal by rauwolscine or  $\alpha_{2A/D}$  gene disruption hence greatly increased) the slope of the pulse number-release relationship. The non-additivity of the effects of  $\alpha_{2A/D}$  gene disruption and rauwolscine clearly showed that the two interventions acted by the



**Fig. 4** Frequency–<sup>3</sup>Hnoradrenaline release relationships in the vas deferens of wild-type mice and mice in which either the  $\alpha_{2A/D}$ -adrenoceptor gene, the  $\alpha_{2B}$ -adrenoceptor gene or the  $\alpha_{2C}$ -adrenoceptor gene had been disrupted. Trains of 30 pulses were applied for each frequency. Tissues were superfused either with rauwolscine-free


medium or with medium containing 1  $\mu$ M rauwolscine. Dotted lines in b to d represent wild-type release in the absence of rauwolscine (from a). Significant differences from wild-type, no rauwolscine: # $p < 0.05$ . Significant effects of rauwolscine: \* $p < 0.05$ . From Scheibner *et al.* (2001b).

same mechanism, i.e. interruption of  $\alpha_2$ -autoinhibition. In these experiments, the only unambiguous autoreceptor was  $\alpha_{2A/D}$  (but see below).

Figure 4 shows the frequency-noradrenaline release relationship in the vas deferens of wild-type,  $\alpha_{2A/D}$ KO,  $\alpha_{2B}$ KO and  $\alpha_{2C}$ KO mice, the pulse number being constant (30). In wild-type vas deferens in the absence of rauwolscine, the curve increased monophasically with frequency, and rauwolscine caused large increases, except at the lowest frequency of 0.03 Hz, and slightly steepened the curve (Fig. 4a). Nothing changed in the  $\alpha_{2B}$ KO vas deferens (Fig. 4c). In  $\alpha_{2C}$ KO vas deferens, the release elicited by 0.3- and 1-Hz trains was slightly higher compared to wild-type, and rauwolscine still caused large increases (Fig. 4d). Deletion of the  $\alpha_{2A/D}$ -adrenoceptor changed the pattern to a greater extent; in the  $\alpha_{2A/D}$ KO vas deferens, release of noradrenaline was considerably increased as compared to wild-type over a wide range of frequencies, the curve was steepened, and rauwolscine increased release only slightly (Fig. 4b). So in the vas deferens,  $\alpha_2$  autoinhibition depressed (and its removal by rauwolscine or  $\alpha_{2A/D}$  gene disruption hence increased)

the slope of the frequency-release relationship. The non-additivity of the effects of  $\alpha_{2A/D}$  gene disruption and rauwolscine again showed that both shared a common mechanism, i.e. interruption of  $\alpha_2$ -autoinhibition. Although the  $\alpha_{2A/D}$ -adrenoceptor was the main autoreceptor in these experiments,  $\alpha_{2C}$ -autoreceptors also became manifest in a twofold manner: as the increase in release caused by  $\alpha_{2C}$  gene disruption (Fig. 4d), and as the increase by rauwolscine that remained in the  $\alpha_{2A/D}$ KO vas deferens (Fig. 4b).

The classical effects of the  $\alpha_2$  antagonist and the new observations on  $\alpha_2$ -adrenoceptor gene-deficient mice concur to demonstrate that presynaptic  $\alpha_2$ -autoreceptors are physiological sites of action of released noradrenaline. A presynaptic negative feedback indeed operates. It helps to shape fundamental properties of transmitter release, namely the pulse number-noradrenaline release relationship and the frequency-noradrenaline release relationship. Both autoreceptors contribute to this physiological function. Possibly  $\alpha_{2C}$ -autoreceptors inhibit mainly release at low frequencies (see Fig. 4d) and  $\alpha_{2A/D}$ -autoreceptors inhibit mainly release at high frequencies (Fig. 4b).



**Fig. 5** Enhancement by phentolamine and rauwolscine of [ $^3\text{H}$ ]noradrenaline release in atria from wild-type mice and mice in which the  $\alpha_{2A/D}$ -adrenoceptor gene had been disrupted. Atria were taken either from newborn or from adult mice. From Schelb *et al.* (2001).

### $\alpha_2$ -Autoreceptors: postnatal development

Presynaptic  $\alpha_2$ -autoreceptors operate already at birth, both in the brain (Wemer and Mulder 1981) and in the periphery (Guimarães *et al.* 1994). The question now to be raised is whether  $\alpha_{2A/D}$ - and  $\alpha_{2C}$ -autoreceptors agree or differ in their development. Recent evidence suggest that they differ, at least in the peripheral tissues where the  $\alpha_{2C}$ -receptors contribute notably to autoinhibition. In support of this view, Fig. 5 shows  $\alpha_2$ -autoinhibition in atria of newborn and adult wild-type and  $\alpha_{2A/D}$ KO mice, the degree of autoinhibition being indicated by the noradrenaline release-enhancing effect of the antagonists phentolamine and rauwolscine. In wild-type atria, the antagonists greatly increased the release of noradrenaline, irrespective of whether the hearts were taken from newborn or adult animals (Fig. 5a). In  $\alpha_{2A/D}$ KO atria, in contrast, the antagonists caused marked increases only when the hearts were taken from adults (Fig. 5b).

$\alpha_{2C}$ -Autoinhibition is the inhibition (revealed by the antagonist-induced increases) remaining in  $\alpha_{2A/D}$ KO tissues. It is minimal in atria of newborn mice and much more marked in adults (Fig. 5b).  $\alpha_{2A/D}$ -Autoinhibition is the difference in inhibition (revealed by the antagonist-induced increases) between wild-type (Fig. 5a) and  $\alpha_{2A/D}$ KO tissues (Fig. 5b). It is large in atria of newborn mice and becomes less dominant in adults. So the first  $\alpha_2$ -autoreceptors to appear in atria are  $\alpha_{2A/D}$ ; they mediate the (already substantial)  $\alpha_2$ -autoinhibition in wild-type atria at birth and do not gain much in efficiency later.  $\alpha_{2C}$ -Autoreceptors, in contrast, seem to be expressed, or at least to become functional, only during postnatal development. A similar differential development was found in the vas deferens (Schelb *et al.* 2001).

### Outlook

Research on presynaptic autoreceptors in general and  $\alpha_2$ -autoreceptors in particular has matured in its third decade. Greeted with some surprise in the early seventies, the autoreceptors are now established elements of the regulation of neurones. As to the next decade of research, one may wish to see presynaptic  $\alpha_2$ -autoreceptors visualized as beautifully in the membrane of noradrenergic terminal axons as certain metabotropic glutamate autoreceptors in the membrane of glutamatergic axons (Takumi *et al.* 1999). One may also wish to see the presynaptic signal transduction elucidated as completely, step by step, as the signal transduction following activation of soma-dendritic  $\alpha_2$ -autoreceptors. Lastly, the relative tasks of  $\alpha_{2A/D}$ - and  $\alpha_{2C}$ -autoreceptors will have to be discovered, and one will have to see whether, contrary to expectation,  $\alpha_{2B}$ -adrenoceptors also may serve as autoreceptors under certain conditions, a possibility for which there is some, but scant, evidence (Scheibner *et al.* 2001b).

### References

- Allgaier C., Feuerstein T. J., Jackisch R. and Hertting G. (1985) Islet-activating protein (pertussis toxin) diminishes  $\alpha_2$ -adrenoceptor mediated effects on noradrenaline release. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **331**, 235–239.
- Altman J. D., Trendelenburg A. U., MacMillan L., Bernstein D., Limbird L., Starke K., Kobilka B. K. and Hein L. (1999) Abnormal regulation of the sympathetic nervous system in  $\alpha_{2A}$ -adrenoceptor knockout mice. *Mol. Pharmacol.* **56**, 154–161.
- Arima J., Kubo C., Ishibashi H. and Akaike N. (1998)  $\alpha_2$ -Adrenoceptor-mediated potassium currents in acutely dissociated rat locus coeruleus neurones. *J. Physiol.* **508**, 57–66.
- Boehm S. and Huck S. (1996) Inhibition of N-type calcium channels: the only mechanism by which presynaptic  $\alpha_2$ -autoreceptors control sympathetic transmitter release. *Eur. J. Neurosci.* **8**, 1924–1931.
- Boehm S., Huck S., Drobny H. and Singer E. A. (1992) Pertussis toxin abolishes the inhibition of  $\text{Ca}^{2+}$  currents and of noradrenaline

- release via  $\alpha_2$ -adrenoceptors in chick sympathetic neurons. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **345**, 606–609.
- Bylund D. B., Eikenberg D. C., Hieble J. P., Langer S. Z., Lefkowitz R. J., Minneman K. P., Molinoff P. B., Ruffolo R. R. and Trendelenburg U. (1994) International Union of Pharmacology nomenclature of adrenoceptors. *Pharmacol. Rev.* **46**, 121–136.
- Carlsson A. (1975) Dopaminergic autoreceptors, in *Chemical Tools in Catecholamine Research*, Vol. II (Almgren O., Carlsson A. and Engel J., eds), pp. 219–225. North-Holland Publishing Co., Amsterdam.
- Delmas P., Abogadie F. C., Milligan G., Buckley N. J. and Brown D. A. (1999)  $\beta\gamma$  dimers derived from  $G_o$  and  $G_i$  proteins contribute different components of adrenergic inhibition of  $Ca^{2+}$  channels in rat sympathetic neurones. *J. Physiol.* **518**, 23–36.
- Docherty J. R. (1998) Subtypes of functional  $\alpha_1$ - and  $\alpha_2$ -adrenoceptors. *Eur. J. Pharmacol.* **361**, 1–15.
- Feuerstein T. J., Huber B., Vetter J., Aranda H., van Velthoven V. and Limberger N. (2000) Characterization of the  $\alpha_2$ -adrenoceptor subtype, which functions as  $\alpha_2$ -autoreceptor in human neocortex. *J. Pharmacol. Exp. Ther.* **294**, 356–362.
- Göbel I., Trendelenburg A. U., Cox S. L., Meyer A. and Starke K. (2000) Electrically evoked release of [ $^3H$ ]noradrenaline from mouse cultured sympathetic neurons: release-modulating heteroreceptors. *J. Neurochem.* **75**, 2087–2094.
- Göthert M. (1977) Effects of presynaptic modulators on  $Ca^{2+}$ -induced noradrenaline release from cardiac sympathetic nerves. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **300**, 267–272.
- Guimarães S., Moura D., Paiva M. Q. and Vaz-da-Silva M. J. (1994) Lack of pre- and postjunctional beta adrenoceptor-mediated effects in the canine saphenous vein at birth. *J. Pharmacol. Exp. Ther.* **268**, 990–995.
- Guimarães S., Figueiredo I. V., Caramona M. M., Moura D. and Paiva M. Q. (1998) Prejunctional  $\alpha_{2A}$ -autoreceptors in the human gastric and ileocolic arteries. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **358**, 207–211.
- Hein L. (2001) Transgenic models of  $\alpha_2$ -adrenergic receptor subtype function. *Rev. Physiol. Biochem. Pharmacol.* **142**, 161–185.
- Hein L., Altman J. D. and Kobilka B. K. (1999) Two functionally distinct  $\alpha_2$ -adrenergic receptors regulate sympathetic neurotransmission. *Nature* **402**, 181–184.
- Hieble J. P., Ruffolo R. R. and Starke K. (1997) Identification, characterization and subclassification of  $\alpha_2$ -adrenoceptors: an overview. In:  *$\alpha_2$ -Adrenergic Receptors: Structure, Function and Therapeutic Implications* (Lanier S. M. and Limbird L. E., eds), pp. 1–18. Harwood Academic Publishers, Amsterdam.
- Hill C. E., Powis D. A. and Hendry I. A. (1993) Involvement of pertussis toxin-sensitive and -insensitive mechanisms in  $\alpha$ -adrenoceptor modulation of noradrenaline release from rat sympathetic neurones in tissue culture. *Br. J. Pharmacol.* **110**, 281–288.
- Jackisch R., Huang H. Y., Rensing H., Lauth D., Allgaier C. and Hertting G. (1992)  $\alpha_2$ -Adrenoceptor mediated inhibition of exocytotic noradrenaline release in the absence of extracellular  $Ca^{2+}$ . *Eur. J. Pharmacol.* **226**, 245–252.
- Jeong S. W. and Ikeda S. R. (2000) Effect of G protein heterotrimer composition on coupling of neurotransmitter receptors to N-type  $Ca^{2+}$  channel modulation in sympathetic neurons. *Proc. Natl Acad. Sci. USA* **97**, 907–912.
- Kalsner S. (1982) The presynaptic receptor controversy. *Trends Pharmacol. Sci.* **3**, 11–16.
- Kalsner S. and Westfall T. C., eds. (1990) Presynaptic Receptors and the Question of Autoregulation of Neurotransmitter Release. *Ann. NY Acad. Sci.* 604.
- Kaneko S., Akaike A. and Satoh M. (1999) Receptor-mediated modulation of voltage-dependent  $Ca^{2+}$  channels via heterotrimeric G-proteins in neurons. *Jap. J. Pharmacol.* **81**, 324–331.
- Koh D. S. and Hille B. (1997) Modulation by neurotransmitters of catecholamine secretion from sympathetic ganglion neurons detected by amperometry. *Proc. Natl Acad. Sci. USA* **94**, 1506–1511.
- Langer S. Z. (1974) Presynaptic regulation of catecholamine release. *Biochem. Pharmacol.* **23**, 1793–1800.
- Lee A., Rosin D. L. and van Bockstaele E. J. (1998a)  $\alpha_{2A}$ -Adrenergic receptors in the rat nucleus locus coeruleus: subcellular localization in catecholaminergic dendrites, astrocytes, and presynaptic axon terminals. *Brain Res.* **795**, 157–169.
- Lee A., Rosin D. L. and van Bockstaele E. J. (1998b) Ultrastructural evidence for prominent postsynaptic localization of  $\alpha_{2C}$ -adrenergic receptors in catecholaminergic dendrites in the rat nucleus locus coeruleus. *J. Comp. Neurol.* **394**, 218–229.
- Limberger N., Trendelenburg A. U. and Starke K. (1992) Pharmacological characterization of presynaptic  $\alpha_2$ -autoreceptors in rat submaxillary gland and heart atrium. *Br. J. Pharmacol.* **107**, 246–255.
- Limberger N., Funk L., Trendelenburg A. U. and Starke K. (1995) Subclassification of presynaptic  $\alpha_2$ -adrenoceptors:  $\alpha_{2A}$ -autoreceptors in rabbit atria and kidney. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **352**, 31–42.
- Link R., Daunt D., Barsh G., Chruscinski A. and Kobilka B. (1992) Cloning of two mouse genes encoding  $\alpha_2$ -adrenergic receptor subtypes and identification of a single amino acid in the mouse  $\alpha_2$ -C10 homolog responsible for an interspecies variation in antagonist binding. *Mol. Pharmacol.* **42**, 16–27.
- MacDermott A. B., Role L. W. and Siegelbaum S. A. (1999) Presynaptic ionotropic receptors and the control of transmitter release. *Annu. Rev. Neurosci.* **22**, 443–485.
- Mateo Y. and Meana J. J. (1999) Determination of the somatodendritic  $\alpha_2$ -adrenoceptor subtype located in rat locus coeruleus that modulates cortical noradrenaline release in vivo. *Eur. J. Pharmacol.* **379**, 53–57.
- Monaghan D. T., Bridges R. J. and Cotman C. W. (1989) The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. *Annu. Rev. Pharmacol. Toxicol.* **29**, 365–402.
- Nicholas A. P., Pieribone V. and Hökfelt T. (1993) Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: an in situ hybridization study. *J. Comp. Neurol.* **328**, 575–594.
- Nörenberg W., Schöffel E., Szabo B. and Starke K. (1997) Subtype determination of soma-dendritic  $\alpha_2$ -autoreceptors in slices of rat locus coeruleus. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **356**, 159–165.
- Olli-Lähdesmäki T., Kallio J. and Scheinin M. (1999) Receptor subtype-induced targeting and subtype-specific internalization of human  $\alpha_2$ -adrenoceptors in PC12 cells. *J. Neurosci.* **19**, 9281–9288.
- Rosin D. L., Zeng D., Stornetta R. L., Norton F. R., Riley T., Okusa M. D., Guyenet P. G. and Lynch K. R. (1993) Immunohistochemical localization of  $\alpha_{2A}$ -adrenergic receptors in catecholaminergic and other brainstem neurons in the rat. *Neuroscience* **56**, 139–155.
- Rosin D. L., Talley E. M., Lee A., Stornetta R. L., Gaylinn B. D., Guyenet P. G. and Lynch K. R. (1996) Distribution of  $\alpha_{2C}$ -adrenergic receptor-like immunoreactivity in the rat central nervous system. *J. Comp. Neurol.* **372**, 135–165.
- Rump L. C., Bohmann C., Schaible U., Schöllhorn J. and Limberger N. (1995)  $\alpha_{2C}$ -Adrenoceptor-modulated release of noradrenaline in human right atrium. *Br. J. Pharmacol.* **116**, 2617–2624.
- Scheibner J., Trendelenburg A. U., Hein L. and Starke K. (2001a)



- $\alpha_2$ -Adrenoceptors modulating neuronal serotonin release: a study in  $\alpha_2$ -adrenoceptor subtype-deficient mice. *Br. J. Pharmacol.* **132**, 925–933.
- Scheibner J., Trendelenburg A. U., Hein L. and Starke K. (2001b) Frequency-noradrenaline release relationships examined in  $\alpha_{2A}$ -,  $\alpha_{2B}$ - and  $\alpha_{2C}$ -adrenoceptor-deficient mice. *Naunyn-Schmiedeberg's Arch. Pharmacol.* in press.
- Scheinin M., Lomasney J. W., Hayden-Hixson D. M., Schambra U. B., Caron M. G., Lefkowitz R. J. and Freneau R. T. (1994) Distribution of  $\alpha_2$ -adrenergic receptor subtype gene expression in rat brain. *Mol. Brain Res.* **21**, 133–149.
- Schelh V., Göbel I., Khairallah L., Zhou H., Cox S. L., Trendelenburg A. U., Hein L. and Starke K. (2001) Postnatal development of presynaptic receptors that modulate noradrenaline release in the mouse. *Naunyn-Schmiedeberg's Arch. Pharmacol.* in press.
- Schwartz D. D. (1997) Activation of alpha-2 adrenergic receptors inhibits norepinephrine release by a pertussis toxin-insensitive pathway independent of changes in cytosolic calcium in cultured rat sympathetic neurons. *J. Pharmacol. Exp. Ther.* **282**, 248–255.
- Smith A. B. and Cunnane T. C. (1998)  $\omega$ -Conotoxin GVIA-resistant neurotransmitter release from postganglionic sympathetic nerves in the guinea-pig vas deferens and its modulation by presynaptic receptors. *Br. J. Pharmacol.* **123**, 167–172.
- Starke K. (1972) Influence of extracellular noradrenaline on the stimulation-evoked secretion of noradrenaline from sympathetic nerves: evidence for an  $\alpha$ -receptor-mediated feed-back inhibition of noradrenaline release. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **275**, 11–23.
- Starke K. (1987) Presynaptic  $\alpha$ -autoreceptors. *Rev. Physiol. Biochem. Pharmacol.* **107**, 73–146.
- Starke K. and Montel H. (1974) Influence of drugs with affinity for  $\alpha$ -adrenoceptors on noradrenaline release by potassium, tyramine and dimethylphenylpiperazinium. *Eur. J. Pharmacol.* **27**, 273–280.
- Starke K., Göthert M. and Kilbinger H. (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. *Physiol. Rev.* **69**, 864–989.
- Takumi Y., Matsubara A., Rinvik E. and Ottersen O. P. (1999) The arrangement of glutamate receptors in excitatory synapses. *Ann. N.Y. Acad. Sci.* **868**, 474–482.
- Trendelenburg A. U., Limberger N. and Starke K. (1993) Presynaptic  $\alpha_2$ -autoreceptors in brain cortex:  $\alpha_{2D}$  in the rat and  $\alpha_{2A}$  in the rabbit. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **348**, 35–45.
- Trendelenburg A. U., Limberger N. and Rump L. C. (1994a)  $\alpha_2$ -Adrenergic receptors of the  $\alpha_{2C}$  subtype mediate inhibition of norepinephrine release in human kidney cortex. *Mol. Pharmacol.* **45**, 1168–1176.
- Trendelenburg A. U., Trendelenburg M., Starke K. and Limberger N. (1994b) Release-inhibiting  $\alpha_2$ -adrenoceptors at serotonergic axons in rat and rabbit brain cortex: evidence for pharmacological identity with  $\alpha_2$ -autoreceptors. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **349**, 25–33.
- Trendelenburg A. U., Sutej I., Wahl C. A., Molderings G. J., Rump L. C. and Starke K. (1997) A re-investigation of questionable subclassifications of presynaptic  $\alpha_2$ -autoreceptors: rat vena cava, rat atria, human kidney and guinea-pig urethra. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **356**, 721–737.
- Trendelenburg A. U., Hein L., Gaiser E. G. and Starke K. (1999) Occurrence, pharmacology and function of presynaptic  $\alpha_2$ -autoreceptors in  $\alpha_{2A/D}$ -adrenoceptor-deficient mice. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **360**, 540–551.
- Trendelenburg A. U., Nörenberg W., Hein L., Meyer A. and Starke K. (2001a)  $\alpha_2$ -Adrenoceptor-mediated inhibition of cultured sympathetic neurons: changes in  $\alpha_{2A/D}$ -adrenoceptor-deficient mice. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **363**, 110–119.
- Trendelenburg A. U., Klebroff W., Hein L. and Starke K. (2001b) A study of presynaptic  $\alpha_2$ -autoreceptors in  $\alpha_{2A/D}$ -,  $\alpha_{2B}$ - and  $\alpha_{2C}$ -adrenoceptor-deficient mice. *Naunyn-Schmiedeberg's Arch. Pharmacol.* in press.
- Vidovic M., Cohen D. and Hill C. E. (1994) Identification of  $\alpha_2$  adrenergic receptor gene expression in sympathetic neurones using polymerase chain reaction and in situ hybridization. *Mol. Brain Res.* **22**, 49–56.
- Wahl C. A., Trendelenburg A. U. and Starke K. (1996) Presynaptic  $\alpha_2$ -autoreceptors in mouse heart atria: evidence for the  $\alpha_{2D}$  subtype. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **354**, 253–261.
- Wang R., MacMillan L. B., Freneau R. T., Magnuson M. A., Lindner J. and Limbird L. E. (1996) Expression of  $\alpha_2$ -adrenergic receptor subtypes in the mouse brain: evaluation of spatial and temporal information imparted by 3 kb of 5' regulatory sequence for the  $\alpha_{2A}$ AR-receptor gene in transgenic animals. *Neuroscience* **74**, 199–218.
- Wemer J. and Mulder A. H. (1981) Postnatal development of presynaptic alpha-adrenoceptors in rat cerebral cortex: studies with brain slices and synaptosomes. *Brain Res.* **208**, 299–309.
- Winzer-Serhan U. H., Raymon H. K., Broide R. S., Chen Y. and Leslie F. M. (1997a) Expression of  $\alpha_2$  adrenoceptors during rat brain development – I.  $\alpha_{2A}$  messenger RNA expression. *Neuroscience* **76**, 241–260.
- Winzer-Serhan U. H., Raymon H. K., Broide R. S., Chen Y. and Leslie F. M. (1997b) Expression of  $\alpha_2$  adrenoceptors during rat brain development – II.  $\alpha_{2C}$  messenger RNA expression and [ $^3$ H]rauwolscine binding. *Neuroscience* **76**, 261–272.